WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > AJA Pharmaceutical Industries Co. Ltd.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Business Insights
OptimizeRx Corporation | March 16, 2022
OptimizeRx Corp. a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced a definitive agreement to acquire the EvinceMed platform and related assets. EvinceMed is a leader in delivering end-to-end automation for specialty pharmaceutical transactions. The acquisition includes the full Market Access Management Platform supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of af...
AbCellera | May 04, 2022
AbCellera and Empirico Inc. announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights PlatformTM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets. Following the rapid progress of their first collaborative program, which identified a lead candidate against an undisclosed G protein-coupled receptor target in less than 12 ...
BioSpace | February 27, 2020
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders. Asit Parikh, the head of Takeda’s Gastroenterology Therapeutic Area Unit told BioSpace in an email that the acquisition of PvP and its celiac asset Kuma062, now known as TAK-062, as well last fall’s acquisition of the license for a first-in-class celiac trea...
Globenewswire | May 09, 2023
Eyenovia, Inc. an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first a...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE